Pharmacia Articles
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Review of eplerenone gets underway in USA
11 February 2002
Fougera first to market generic clindamycin lotion
11 February 2002
NICE "should appraise innovative new drugs a year before launch"
4 February 2002
Pharmacia buys stake in Abbott India
4 February 2002
Roche and deCODE move from target to drug discovery in alliance
4 February 2002
Osamu Yamaki, moves up at Pharmacia KK
28 January 2002
Pharmacia Canada has named Paladin Labs as the exclusive Canadian distributorhyperprolactinemia, Estring (estradiol vagi
28 January 2002
Pharmacia & Paladin sign Canadian distribution deal
28 January 2002
Miravant's SnET2 Ph III disappoints.
21 January 2002
Drug delay concerns hit NeoPharm.
21 January 2002
deCODE and Pharmacia Corp form pharmacogenomics alliance.
21 January 2002
Caraco gets FDA approval for oxaprozin.
21 January 2002
Biovail files new form of sleep drug zolpidem.
21 January 2002
Better outlook for Euro biotech for 2002, says Lehman Bros.
21 January 2002
Kendle International enters three-year deal with Pharmacia Corp
14 January 2002
Rheumatoid arthritis market forecasts
14 January 2002
Israel biotech project under threat
14 January 2002
Pharmacia appointment
7 January 2002
Kaken takes over Cytotec sales in Japan
7 January 2002
Pharmacia returns Ambien rights to Sanofi-Synthelabo
7 January 2002
Gyros AB raises 309 million kroner
7 January 2002
Kaken takes over Cytotec sales in Japan
24 December 2001
Pharmacia returns Ambien rights to Sanofi-Synthelabo
21 December 2001
Gyros AB raises 309 million kroner
19 December 2001
Quntiles links up with Pharmacia Corp
12 December 2001
Stock Commentary - Europe
6 December 2001
Pharmion placement raises $65 million
6 December 2001
Evotec signs major deal with Merck & Co
5 December 2001
Pharmacia expecting 6%-10% increase in 2002 earnings per share
4 December 2001
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Pharma sued over US Medicare drug prices
27 November 2001
Pramipexole cleared as monotherapy in PD
26 November 2001
Pharmacia's Somavert works in acromegaly
26 November 2001
Chiron sepsis drug fails at final hurdle
21 November 2001
Update: Pharmacia gets US approval for Celebrex follow-up Bextra
20 November 2001
New owners at Biovitrum spin-off
20 November 2001
Pharmacia's second COX-2 cleared by FDA
19 November 2001
Galapagos signs deal with Pharmacia
16 November 2001
Aventis to sell Synercid in Japan
15 November 2001
Pharmacia reduces stake in Biovitrum
12 November 2001
Orion benefits from Pharmacia payment
7 November 2001
ImClone's Erbitux filed for refractory colorectal cancer in USA
2 November 2001
Pharmacia starts new study of LMWH drug
1 November 2001
Biotech now offers chance of great growth, says Commerzbank
1 November 2001
France's Sanofi-Synthelabo continues to outperform competitors
26 October 2001
Survey shows women not choosing most effective contraceptives
24 October 2001
Pharmacia EPS rises 24% in third quarter
24 October 2001
Celebrex approved for pain indication in USA
24 October 2001
Pharmacia launches Xalacom in UK
22 October 2001
Pharmacia appointment
18 October 2001
Cetek raises $14 million
12 October 2001
Amersham's Andrew Webb joins DxS
11 October 2001
Ciphergen and Pfizer in biomarker pact
9 October 2001
Alprostadil likely to gain new ED patients
9 October 2001
NeoPharm planning share buybacks
1 October 2001
Stock Commentary - Europe
27 September 2001
Biacore signs up Millennium as first partner for S51 system
26 September 2001
Merck & Co warned over Vioxx promotion
25 September 2001
Datamonitor expresses views on Celebrex vs Vioxx; Novartis ADHD drug
24 September 2001
Scotland's HAI costs "underestimated"
14 September 2001
Stock Commentary - Europe
13 September 2001
Interneuron begins Ph III trospium trial
7 September 2001
Stock Commentary - Europe
6 September 2001
Sanofi-Synthelabo first-half net income rises 50% - UPDATE
6 September 2001
New guidance for CHF treatment aims at non-cardiologists
4 September 2001
Norak/Amersham agreement
30 August 2001
Stock Commentary - Europe
30 August 2001
Stock Commentary - New York
30 August 2001
Orion signs major deal with Pharmacia
29 August 2001
TNF-alpha inhibitor sales forecast to soar
22 August 2001
Axert migraine therapy launched by Pharmacia in USA
22 August 2001
Urinary incontinence market forecasts
10 August 2001
Exelixis delivers more targets to Pharmacia
9 August 2001
EU approves Pharmacia's Xalcom
9 August 2001
Japan pharma share prices to August 6
7 August 2001
Celltech reaches target with arthritis drug
30 July 2001
Sanofi-Synthelabo 1st-half sales up 15%
30 July 2001
Sanofi-Synthelabo 1st-half sales up 15%
27 July 2001
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
